HRP20171357T1 - Ograničeni teški lanac imunoglobulina u miševa - Google Patents
Ograničeni teški lanac imunoglobulina u miševa Download PDFInfo
- Publication number
- HRP20171357T1 HRP20171357T1 HRP20171357TT HRP20171357T HRP20171357T1 HR P20171357 T1 HRP20171357 T1 HR P20171357T1 HR P20171357T T HRP20171357T T HR P20171357TT HR P20171357 T HRP20171357 T HR P20171357T HR P20171357 T1 HRP20171357 T1 HR P20171357T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- gene
- human
- segments
- mouse
- Prior art date
Links
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 title claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 title claims 3
- 241000699670 Mus sp. Species 0.000 title claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 39
- 241000699666 Mus <mouse, genus> Species 0.000 claims 19
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Miš čiji je lokus teškog lanca endogenog imunoglobulina ograničen tako da se sastoji od jednog segmenta ljudskog VH gena, jednog ili više segmenata ljudskog DH gena i jednog ili više segmenata ljudskog JH gena i koji se ne sastoji od funkcionalnog lokusa varijabilne regije teškog lanca endogenog imunoglobulina; miš se nadalje sastoji od jednog ili više segmenata VL gena ljudskog imunoglobulina operativno povezanih s jednim ili više segmenata JL gena, pri čemu su jedan segment ljudskog VH gena, jedan ili više segmenata ljudskog DH gena, i jedan ili više segmenata ljudskog JH gena operativno povezani s genom konstantne regije teškog lanca neljudskog imunoglobulina, pri čemu je jedan segment ljudskog VH gena VH1-69 ili polimorfna varijanta tog gena.
2. Miš prema patentnom zahtjevu 1, pri čemu miš sadrži brisanje svih endogenih segmenata VH, DH, i JH gena.
3. Miš t prema patentnom zahtjevu 1 ili prema patentnom zahtjevu 2, pri čemu jedan segment ljudskog VH gena, jedan ili više segmenata ljudskog DH gena, i jedan ili više segmenata ljudskog JH gena zamjenjuju sve endogene segmente VH, DH, i JH gena na lokusu teškog lanca endogenog imunoglobulina u zametnoj liniji navedenih miševa.
4. Miš prema patentnom zahtjevu 3 u kojem jedan ili više segmenata ljudskog VL gena i jedan ili više segmenata ljudskog JL gena zamjenjuju sve endogene segmente VL i JL gena na lokusu laganog lanca endogenog imunoglobulina.
5. Miš prema bilo kom od predhodnih patentnih zahtjeva, pri čemu se jedan ili više segmenata ljudskog VL gena i/ili jedan ili više segmenata ljudskog JL gena odabire iz segmenata ljudskog κ i ljudskog λ gena.
6. Miš prema bilo kom od predhodnih patentnih zahtjeva, pri čemu su jedan ili više segmenata VL gena ljudskog imunoglobulina i jedan ili više segmenata JL gena operativno povezani s neljudskim konstantnim genom laganog lanca, na primjer mišjim ili štakorskim κ ili λ genom konstantne regije.
7. Miš prema bilo kom od predhodnih patentnih zahtjeva, pri čemu su jedan segment ljudskog VH gena, jedan ili više segmenata ljudskog DH gena i jedan ili više segmenata JH gena operativno povezani s mišjim ili štakorskim genom konstantne regije imunoglobulina.
8. Miš prema bilo kom od predhodnih patentnih zahtjeva , pri čemu su jedan segment ljudskog VH gena, jedan ili više segmenata ljudskog DH gena i jedan ili više segmenata JH gena operativno povezani s mišjim IgM genom konstantne regije.
9. Stanica ili tkivo izvedeno iz miša prema bilo kom od predhodnih patentnih zahtjeva.
10. Metoda izrade slijeda nukleinske kiseline kojom se kodira ljudska VH domena gena sastoji se od sljedećih koraka: (a) imunizacija miša bilo koje prethodne tvrdnje s antigenom od interesa; (b) dopuštanje da navedeni miš razvije imunosni odgovor na antigen od interesa; i (c) uzimanje slijeda nukleinske kiseline VH regije gena imunoglobulina kojim se kodira ljudska VH domena gena od navedenog miša.
11. Metoda prema patentnom zahtjevu 10, pri čemu slijed nukleinske kiseline regije VH imunoglobulina: (a) čini slijed koji je barem 75 % identičan identifikacijskim brojevima slijeda SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 ili SEQ ID NO: 58; ili (b) čini identifikacijske brojeve slijeda SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58 ili polimorfnu varijantu tog slijeda; ili (c) kodira protein koji je barem 75 % identičan identifikacijskim brojevima slijeda SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57 ili SEQ ID NO: 59.
12. Upotreba miša prema prema bilo kom od patentnih zahtjeva od 1 do 8 u metodi proizvodnje slijeda nukleinske kiseline kojim se kodira varijabilna domena ljudskog teškog lanca.
13. Upotreba prema prema patentnom zahtjevu 12, pri čemu varijabilna domena ljudskog teškog lanca ima karakteristike ljudskih sljedova FR1-CDR1-FR2-CDR2-FR3 izvedenih iz polimorfnog segmenta ljudskog VH 1-69 gena.
14. Upotreba miša prema prema bilo kom od patentnih zahtjeva od 1 do 8 za izradu ljudskog protutijela, pri čemu se ljudsko protutijelo sastoji od varijabilne domene teškog lanca izvedene iz preuređenog segmenta ljudskog VH1-69 gena ili njegove polimorfne varijante, pri čemu je preuređeni segment ljudskog VH1-69 gena barem 75 % identičan identifikacijskim brojevima sljedova SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 ili SEQ ID NO: 58.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547974P | 2011-10-17 | 2011-10-17 | |
US201261597969P | 2012-02-13 | 2012-02-13 | |
US201261658459P | 2012-06-12 | 2012-06-12 | |
PCT/US2012/060487 WO2013059230A1 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
EP12783456.2A EP2627773B1 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171357T1 true HRP20171357T1 (hr) | 2017-12-15 |
Family
ID=47144131
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220253TT HRP20220253T1 (hr) | 2011-10-17 | 2012-10-17 | Miševi s ograničenim teškim lancem imunoglobulina |
HRP20171357TT HRP20171357T1 (hr) | 2011-10-17 | 2017-09-11 | Ograničeni teški lanac imunoglobulina u miševa |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220253TT HRP20220253T1 (hr) | 2011-10-17 | 2012-10-17 | Miševi s ograničenim teškim lancem imunoglobulina |
Country Status (26)
Country | Link |
---|---|
US (5) | US10246509B2 (hr) |
EP (3) | EP4074833A1 (hr) |
JP (6) | JP6271435B2 (hr) |
KR (6) | KR20160098514A (hr) |
CN (3) | CN104024418B (hr) |
AU (4) | AU2012326283C1 (hr) |
BR (1) | BR112014008775A8 (hr) |
CA (1) | CA2850534A1 (hr) |
CY (2) | CY1119335T1 (hr) |
DK (2) | DK3216871T3 (hr) |
ES (2) | ES2640139T3 (hr) |
HR (2) | HRP20220253T1 (hr) |
HU (2) | HUE057680T2 (hr) |
IL (5) | IL292030B2 (hr) |
IN (1) | IN2014CN03572A (hr) |
LT (2) | LT3216871T (hr) |
MX (1) | MX355062B (hr) |
MY (1) | MY172946A (hr) |
PL (2) | PL3216871T3 (hr) |
PT (2) | PT3216871T (hr) |
RS (2) | RS56458B1 (hr) |
RU (2) | RU2743589C2 (hr) |
SG (3) | SG11201401181YA (hr) |
SI (2) | SI3216871T1 (hr) |
WO (1) | WO2013059230A1 (hr) |
ZA (1) | ZA201402455B (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
HUE045591T2 (hu) | 2010-02-08 | 2019-12-30 | Regeneron Pharma | Közönséges könnyûláncú egér |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
RU2750219C2 (ru) | 2010-08-02 | 2021-06-24 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
RS59661B2 (sr) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 miševi |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CA2859408C (en) | 2011-12-20 | 2020-06-16 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PL3597037T3 (pl) * | 2012-06-12 | 2021-10-25 | Regeneron Pharmaceuticals, Inc. | Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny |
MY178882A (en) * | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2015112790A2 (en) * | 2014-01-24 | 2015-07-30 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
ES2762640T3 (es) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | Proteínas VL de unión a antígeno que exhiben diferentes características de unión |
WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US20170121399A1 (en) | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
CN108777951B (zh) | 2016-01-13 | 2021-11-05 | 瑞泽恩制药公司 | 具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途 |
RU2018130010A (ru) | 2016-02-16 | 2020-03-17 | Регенерон Фармасьютикалз, Инк. | Животные, отличные от человека, имеющие мутантный ген кинурениназы |
KR102628909B1 (ko) | 2016-05-20 | 2024-01-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
PT3462853T (pt) | 2016-06-03 | 2023-04-21 | Regeneron Pharma | Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena |
AU2017391167B2 (en) | 2016-11-04 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
CN108265035A (zh) * | 2016-12-30 | 2018-07-10 | 深圳先进技术研究院 | 一种进化噬菌体宿主特异性的方法 |
US20210345591A1 (en) | 2017-12-05 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
CN112040769B (zh) | 2018-03-24 | 2023-05-16 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途 |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
CN112312766A (zh) | 2018-06-14 | 2021-02-02 | 瑞泽恩制药公司 | 在免疫球蛋白重链编码序列中具有dh-dh重排能力的非人动物 |
US20220330532A1 (en) | 2019-06-05 | 2022-10-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
CN114901678A (zh) | 2019-12-02 | 2022-08-12 | 瑞泽恩制药公司 | 肽-mhc ii蛋白构建体及其用途 |
JP2023540808A (ja) | 2020-09-11 | 2023-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗原特異的抗体の同定及び産生 |
JP2024500399A (ja) | 2020-12-16 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化Fcアルファ受容体を発現するマウス |
TW202241934A (zh) * | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 編碼錨定修飾抗體之核酸及其用途 |
WO2023179620A1 (en) * | 2022-03-21 | 2023-09-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP1978033A3 (en) * | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
AU5043200A (en) | 1999-05-27 | 2000-12-18 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
JP4115281B2 (ja) | 2001-05-11 | 2008-07-09 | キリンファーマ株式会社 | ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物 |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004257292A1 (en) | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
CN101076542A (zh) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
EP1874817A2 (en) | 2005-04-29 | 2008-01-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
LT2602323T (lt) | 2007-06-01 | 2018-04-10 | Open Monoclonal Technology, Inc. | Kompozicijos ir būdai endogeninių imunoglobulinų genams slopinti ir transgeniniams žmogaus idiotipo antikūnams gaminti |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009097006A2 (en) * | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
WO2009042589A1 (en) * | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
KR20100103810A (ko) | 2007-12-10 | 2010-09-28 | 알리바 바이오파마수티컬스, 아이엔씨. | 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법 |
ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
CN102099378B (zh) * | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
US20110123527A1 (en) | 2008-05-23 | 2011-05-26 | Hiroaki Shizuya | Method of generating single vl domain antibodies in transgenic animals |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
ES2613730T3 (es) | 2008-12-18 | 2017-05-25 | Erasmus University Medical Center Rotterdam | Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
KR20120027055A (ko) * | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
SG181477A1 (en) | 2009-12-10 | 2012-07-30 | Regeneron Pharma | Mice that make heavy chain antibodies |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
HUE045591T2 (hu) | 2010-02-08 | 2019-12-30 | Regeneron Pharma | Közönséges könnyûláncú egér |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
NZ605966A (en) | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
RU2750219C2 (ru) | 2010-08-02 | 2021-06-24 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
EP2638155A1 (en) | 2010-11-08 | 2013-09-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
RS59661B2 (sr) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 miševi |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
CA2859408C (en) * | 2011-12-20 | 2020-06-16 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
MY172730A (en) | 2012-03-16 | 2019-12-11 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PL3597037T3 (pl) | 2012-06-12 | 2021-10-25 | Regeneron Pharmaceuticals, Inc. | Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny |
MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
PL2967013T3 (pl) | 2013-03-13 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Mysz, w której zachodzi ekspresja ograniczonego repertuaru lekkiego łańcucha immunoglobuliny |
-
2012
- 2012-10-17 HU HUE17163115A patent/HUE057680T2/hu unknown
- 2012-10-17 PL PL17163115T patent/PL3216871T3/pl unknown
- 2012-10-17 BR BR112014008775A patent/BR112014008775A8/pt not_active Application Discontinuation
- 2012-10-17 IN IN3572CHN2014 patent/IN2014CN03572A/en unknown
- 2012-10-17 RS RS20170893A patent/RS56458B1/sr unknown
- 2012-10-17 EP EP21208060.0A patent/EP4074833A1/en active Pending
- 2012-10-17 JP JP2014535991A patent/JP6271435B2/ja active Active
- 2012-10-17 CN CN201280062449.XA patent/CN104024418B/zh active Active
- 2012-10-17 PT PT171631153T patent/PT3216871T/pt unknown
- 2012-10-17 DK DK17163115.3T patent/DK3216871T3/da active
- 2012-10-17 LT LTEP17163115.3T patent/LT3216871T/lt unknown
- 2012-10-17 RU RU2016139418A patent/RU2743589C2/ru active
- 2012-10-17 CA CA2850534A patent/CA2850534A1/en active Pending
- 2012-10-17 SG SG11201401181YA patent/SG11201401181YA/en unknown
- 2012-10-17 RS RS20220181A patent/RS62942B1/sr unknown
- 2012-10-17 SG SG10202010120XA patent/SG10202010120XA/en unknown
- 2012-10-17 EP EP17163115.3A patent/EP3216871B1/en active Active
- 2012-10-17 US US13/653,456 patent/US10246509B2/en active Active
- 2012-10-17 PL PL12783456T patent/PL2627773T3/pl unknown
- 2012-10-17 SG SG10201602904VA patent/SG10201602904VA/en unknown
- 2012-10-17 LT LTEP12783456.2T patent/LT2627773T/lt unknown
- 2012-10-17 WO PCT/US2012/060487 patent/WO2013059230A1/en active Application Filing
- 2012-10-17 CN CN201710933685.9A patent/CN108200885B/zh active Active
- 2012-10-17 EP EP12783456.2A patent/EP2627773B1/en active Active
- 2012-10-17 KR KR1020167021090A patent/KR20160098514A/ko active Search and Examination
- 2012-10-17 SI SI201231981T patent/SI3216871T1/sl unknown
- 2012-10-17 KR KR1020147013282A patent/KR20140082824A/ko active Search and Examination
- 2012-10-17 KR KR1020237045077A patent/KR20240006704A/ko not_active Application Discontinuation
- 2012-10-17 IL IL292030A patent/IL292030B2/en unknown
- 2012-10-17 KR KR1020207012383A patent/KR20200047786A/ko not_active IP Right Cessation
- 2012-10-17 ES ES12783456.2T patent/ES2640139T3/es active Active
- 2012-10-17 PT PT127834562T patent/PT2627773T/pt unknown
- 2012-10-17 KR KR1020197021940A patent/KR102148683B1/ko active IP Right Grant
- 2012-10-17 MX MX2014004354A patent/MX355062B/es active IP Right Grant
- 2012-10-17 DK DK12783456.2T patent/DK2627773T3/en active
- 2012-10-17 ES ES17163115T patent/ES2906462T3/es active Active
- 2012-10-17 KR KR1020217028212A patent/KR20210113419A/ko not_active IP Right Cessation
- 2012-10-17 SI SI201231055T patent/SI2627773T1/sl unknown
- 2012-10-17 HR HRP20220253TT patent/HRP20220253T1/hr unknown
- 2012-10-17 MY MYPI2014000810A patent/MY172946A/en unknown
- 2012-10-17 AU AU2012326283A patent/AU2012326283C1/en active Active
- 2012-10-17 RU RU2014118869/10A patent/RU2603090C2/ru active
- 2012-10-17 CN CN201710933842.6A patent/CN108207807B/zh active Active
- 2012-10-17 HU HUE12783456A patent/HUE034321T2/en unknown
-
2013
- 2013-07-17 US US13/944,286 patent/US9932398B2/en active Active
-
2014
- 2014-03-31 IL IL231819A patent/IL231819A0/en active IP Right Grant
- 2014-04-01 ZA ZA2014/02455A patent/ZA201402455B/en unknown
-
2015
- 2015-11-12 JP JP2015222017A patent/JP2016039820A/ja active Pending
-
2016
- 2016-06-17 AU AU2016204127A patent/AU2016204127C1/en active Active
-
2017
- 2017-09-11 HR HRP20171357TT patent/HRP20171357T1/hr unknown
- 2017-09-12 CY CY20171100960T patent/CY1119335T1/el unknown
- 2017-09-27 JP JP2017186356A patent/JP2017221223A/ja active Pending
-
2018
- 2018-05-30 AU AU2018203811A patent/AU2018203811B2/en active Active
- 2018-08-20 IL IL261242A patent/IL261242A/en active IP Right Grant
- 2018-12-27 JP JP2018244321A patent/JP6770568B2/ja active Active
-
2019
- 2019-02-01 US US16/265,825 patent/US11261248B2/en active Active
- 2019-04-11 IL IL265967A patent/IL265967B/en active IP Right Grant
-
2020
- 2020-04-17 US US16/851,902 patent/US20200277371A1/en not_active Abandoned
- 2020-09-25 JP JP2020161346A patent/JP7022803B2/ja active Active
- 2020-12-18 AU AU2020289846A patent/AU2020289846A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282200A patent/IL282200B/en unknown
- 2021-12-29 JP JP2021215393A patent/JP2022048158A/ja not_active Withdrawn
-
2022
- 2022-01-19 US US17/579,185 patent/US20220177572A1/en active Pending
- 2022-02-07 CY CY20221100102T patent/CY1124972T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
HRP20150262T1 (hr) | Miševi sa adam6 | |
HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
HRP20190807T1 (hr) | Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom | |
HRP20211126T1 (hr) | Humanizirane nehumane životinje s ograničenim lokusima imunoglobulinskog teškog lanca | |
HRP20201403T1 (hr) | Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca | |
JP2015519076A5 (hr) | ||
HRP20210916T1 (hr) | Miševi s ljudskim univerzalnim lakim lancem | |
HRP20191680T1 (hr) | Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
JP2015505477A5 (hr) | ||
SG10201900580RA (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
RU2014140239A (ru) | Мышь с общей легкой цепью | |
JP2011182801A5 (hr) | ||
HRP20161551T4 (hr) | Miš sa zajedničkim lakim lancem | |
HRP20230490T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
JP2015502177A5 (hr) | ||
RU2012128856A (ru) | Мыши, которые производят антитела, имеющие только тяжелую цепь | |
WO2015143414A3 (en) | Non-human animals that make single domain binding proteins | |
RU2022109215A (ru) | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl | |
TH169580A (th) | หนูเมาส์ที่มีสายเบาแบบทั่วไป | |
TH169582A (th) | วิธีสำหรับการสร้างไบสเปซิฟิกแอนติบอดีแบบของมนุษย์อย่างสมบูรณ์โดยใช้สายเบาสามัญทั่วไป |